Like Andrew constantly referring to lumpy revenue in each quarterly as an explanation as to why revenue had declined/remain stagnant.... implying that orders were coming in but not recognised in the financials for that quarter. The question is, does his line of BS apply to the Fuji contract? Are labs re-ordering product? Are labs not ordering product and that is why revenue has declined? Maybe ask him why he was issued performance shares too, because I haven't seen any!
Like Andrew constantly referring to lumpy revenue in each...
Add BCT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.910M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 550000 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 1821815 | 8 |
View Market Depth
| Last trade - 16.12pm 04/07/2024 (20 minute delay) ? |
| BCT (ASX) Chart |
Day chart unavailable